Abstract: Assessment of atopic dermatitis (AD) severity is essential for therapeutic decision making and monitoring treatment progress. However, there are a myriad of clinical measurement tools available, some of which are impractical for routine clinical use despite being recommended for clinical trials in AD. For measurement tools to be used in clinical practice, they should be valid, reliable, rapidly completed, and scored, and easily incorporated into existing clinic workflows. This narrative review addresses content, validity, and feasibility, and provides a simplified repertoire of assessments for clinical assessment of AD based on prior evidence and expert opinion. Tools that may be feasible for clinical practice include patient-reported outcomes (eg, dermatology life quality index, patient-oriented eczema measure, numerical rating scales for itch, pain, and sleep disturbance, AD Control Tool, and patient-reported global assessment), and clinician-reported outcomes (eg, body surface area and investigator's global assessment). AD is associated with variable clinical signs, symptoms, extent of lesions, longitudinal course, comorbidities, and impacts. Any single domain is insufficient to holistically characterize AD severity, select therapy, or monitor treatment response. A combination of these tools is recommended to balance completeness and feasibility.
Get full access to this article
View all access options for this article.
References
1.
WeidingerS, NosbaumA, SimpsonE, et al.Good practice intervention for clinical assessment and diagnosis of atopic dermatitis: findings from the atopic dermatitis quality of care initiative. Dermatol Ther, 2022; 35(3):e15259.
2.
HillMK, Kheirandish PishkenariA, BraunbergerTL, et al.Recent trends in disease severity and quality of life instruments for patients with atopic dermatitis: a systematic review. J Am Acad Dermatol, 2016; 75(5):906–917.
3.
ChovatiyaR, SilverbergJI. The heterogeneity of atopic dermatitis. J Drugs Dermatol, 2022; 21(2):172–176.
4.
SilverbergNB.Typical and atypical clinical appearance of atopic dermatitis. Clin Dermatol, 2017; 35(4):354–359.
5.
AllenHB, JonesNP, BowenSE. Lichenoid and other clinical presentations of atopic dermatitis in an inner city practice. J Am Acad Dermatol, 2008; 58(3):503–504.
6.
LiJC, FishbeinA, SingamV, et al.Sleep disturbance and sleep-related impairment in adults with atopic dermatitis: a cross-sectional study. Dermatitis, 2018; 29(5):270–277.
7.
PatelKR, ImmaneniS, SingamV, et al.Association between atopic dermatitis, depression, and suicidal ideation: a systematic review and meta-analysis. J Am Acad Dermatol, 2019; 80(2):402–410.
8.
SilverbergJI, GelfandJM, MargolisDJ, et al. Symptoms and diagnosis of anxiety and depression in atopic dermatitis in U.S. adults. Br J Dermatol, 2019; 181(3):554–565.
9.
YaghmaieP, KoudelkaCW, SimpsonEL. Mental health comorbidity in patients with atopic dermatitis. J Allergy Clin Immunol, 2013; 131(2):428–433.
10.
SchonmannY, MansfieldKE, HayesJF, et al.Atopic eczema in adulthood and risk of depression and anxiety: a population-based cohort study. J Allergy Clin Immunol Pract, 2020; 8(1):248–257.e216.
11.
LeeS, ShinA. Association of atopic dermatitis with depressive symptoms and suicidal behaviors among adolescents in Korea: the 2013 Korean Youth Risk Behavior Survey. BMC Psychiatry, 2017; 17(1):3–3.
12.
Dieris-HircheJ, GielerU, PetrakF, et al.Suicidal ideation in adult patients with atopic dermatitis: a German cross-sectional study. Acta Derm Venereol, 2017; 97(10):1189–1195.
13.
DavisDMR, DruckerAM, AlikhanA, et al.American Academy of Dermatology Guidelines: awareness of comorbidities associated with atopic dermatitis in adults. J Am Acad Dermatol, 2022; 86(6):1335–1336.e1318.
14.
RønnstadATM, Halling-OvergaardAS, HamannCR, et al.Association of atopic dermatitis with depression, anxiety, and suicidal ideation in children and adults: a systematic review and meta-analysis. J Am Acad Dermatol, 2018; 79(3):448–456.e430.
15.
HsuDY, SmithB, SilverbergJI. Atopic dermatitis and hospitalization for mental health disorders in the United States. Dermatitis, 2019; 30(1):54–61.
PongdeeT. Association between atopic dermatitis and attention deficit hyperactivity disorder inU.S. children and adults. Pediatrics, 2017; 140(Supplement 3):S206.
18.
FutamuraM, LeshemYA, ThomasKS, et al.A systematic review of investigator global assessment (IGA) in atopic dermatitis (AD) trials: many options, no standards. J Am Acad Dermatol, 2016; 74(2):288–294.
19.
SchmittJ, SpulsPI, ThomasKS, et al.The Harmonising Outcome Measures for Eczema (HOME) statement to assess clinical signs of atopic eczema in trials. J Allergy Clin Immunol, 2014; 134(4):800–807.
20.
SchmittJ, LanganS, DeckertS, et al.Assessment of clinical signs of atopic dermatitis: a systematic review and recommendation. J Allergy Clin Immunol, 2013; 132(6):1337–1347.
21.
ChalmersJR, SimpsonE, ApfelbacherCJ, et al.Report from the fourth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative). Br J Dermatol, 2016; 175(1):69–79.
22.
SpulsPI, GerbensLAA, SimpsonE, et al.Patient-Oriented Eczema Measure (POEM), a core instrument to measure symptoms in clinical trials: a Harmonising Outcome Measures for Eczema (HOME) statement. Br J Dermatol, 2017; 176(4):979–984.
23.
BasraMKA, FenechR, GattRM, et al.The Dermatology Life Quality Index 1994–2007: a comprehensive review of validation data and clinical results. Br J Dermatol, 2008; 159(5):997–1035.
24.
HeinlD, PrinsenCAC, SachT, et al.Measurement properties of quality-of-life measurement instruments for infants, children and adolescents with eczema: a systematic review. Br J Dermatol, 2017; 176(4):878–889.
25.
BhanotA, VincentR, PetersTJ, et al.Validation of the RECap of AtoPic eczema measure of eczema control for use in dermatology clinics. Clin Exp Dermatol, 2022; 47(2):440–442.
26.
HowellsLM, ChalmersJR, GranS, et al.Development and initial testing of a new instrument to measure the experience of eczema control in adults and children: recap of atopic eczema (RECAP). Br J Dermatol, 2020; 183(3):524–536.
27.
PariserDM, SimpsonEL, GadkariA, et al.Evaluating patient-perceived control of atopic dermatitis: design, validation, and scoring of the Atopic Dermatitis Control Tool (ADCT). Curr Med Res Opin, 2020; 36(3):367–376.
YosipovitchG, ReaneyM, MasteyV, et al.Peak pruritus numerical rating scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis. Br J Dermatol, 2019; 181(4):761–769.
30.
ThomasKS, ApfelbacherCA, ChalmersJR, et al.Recommended core outcome instruments for health-related quality of life, long-term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meeting. Br J Dermatol, 2021; 185(1):139–146.
31.
BarbierN, PaulC, LugerT, et al.Validation of the eczema area and severity index for atopic dermatitis in a cohort of 1550 patients from the pimecrolimus cream 1% randomized controlled clinical trials programme. Br J Dermatol, 2004; 150(1):96–102.
32.
SchmittJ, LanganS, WilliamsHC, European Dermato-EpidemiologyN. What are the best outcome measurements for atopic eczema? A systematic review. J Allergy Clin Immunol, 2007; 120(6):1389–1398.
33.
CharmanC, WilliamsH. Outcome measures of disease severity in atopic eczema. Arch Dermatol, 2000; 136(6):763–769.
34.
KunzB, OranjeAP, LabrèzeL, et al.Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis. Dermatology, 1997; 195(1):10–19.
35.
OranjeAP.Practical issues on interpretation of scoring atopic dermatitis: SCORAD Index, objective SCORAD, patient-oriented SCORAD and Three-Item Severity score. Curr Probl Dermatol, 2011; 41:149–155.
36.
LeshemYA, HajarT, HanifinJM, et al.What the eczema area and severity index score tells us about the severity of atopic dermatitis: an interpretability study. Br J Dermatol, 2015; 172(5):1353–1357.
37.
ChopraR, VakhariaPP, SacotteR, et al.Relationship between EASI and SCORAD severity assessments for atopic dermatitis. J Allergy Clin Immunol, 2017; 140(6):1708–1710.e1701.
38.
SilverbergJI, LeiD, YousafM, et al.Measurement properties of the Rajka–Langeland severity score in children and adults with atopic dermatitis*. Br J Dermatol, 2021; 184(1):87–95.
39.
SimpsonE, BissonnetteR, EichenfieldLF, et al.The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): the development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis. J Am Acad Dermatol, 2020; 83(3):839–846.
40.
ChovatiyaR, SilverbergJI. DESCRIBE-AD: A novel classification framework for atopic dermatitis. J Am Acad Dermatol, 2022; 87(3):541–550.
41.
ChopraR, VakhariaPP, SacotteR, et al.Severity strata for eczema area and severity index (EASI), modified EASI, scoring atopic dermatitis (SCORAD), objective SCORAD, atopic dermatitis severity index and body surface area in adolescents and adults with atopic dermatitis. Br J Dermatol, 2017; 177(5):1316–1321.
42.
SilverbergJI, LeiD, YousafM, et al.Measurement properties of the product of investigator's global assessment and body surface area in children and adults with atopic dermatitis. J Eur Acad Dermatol Venereol, 2021; 35(1):180–187.
43.
SuhTP, RamachandranD, PatelV, et al.Product of investigator global assessment and body surface area (IGAxBSA): a practice-friendly alternative to the eczema area and severity index to assess atopic dermatitis severity in children. J Am Acad Dermatol, 2020; 82(5):1187–1194.
44.
VakhariaPP, ChopraR, SacotteR, et al.Validation of patient-reported global severity of atopic dermatitis in adults. Allergy, 2018; 73(2):451–458.
45.
SilverbergJI, Chiesa FuxenchZC, GelfandJM, et al.Content and construct validity, predictors, and distribution of self-reported atopic dermatitis severity in US adults. Ann Allergy Asthma Immunol, 2018; 121(6):729–734.e724.
46.
SilverbergJI, RangelSM, ShethA, et al.Single-question parent-reported global atopic dermatitis severity: a valid instrument in children. J Am Acad Dermatol, 2023; 88(1):212–215.
47.
VakhariaPP, ChopraR, SacotteR, et al.Severity strata for five patient-reported outcomes in adults with atopic dermatitis. Br J Dermatol, 2018; 178(4):925–930.
48.
SilverbergJI, LaiJ-S, VakhariaPP, et al.Measurement properties of the patient-reported outcomes measurement information system itch questionnaire item banks in adults with atopic dermatitis. J Am Acad Dermatol, 2020; 82(5):1174–1180.
49.
SilverbergJI, LaiJS, PatelKR, et al.Measurement properties of the patient-reported outcomes information system (PROMIS®) itch questionnaire: itch severity assessments in adults with atopic dermatitis*. Br J Dermatol, 2020; 183(5):891–898.
50.
SilverbergJI, DeLozierA, SunL, et al.Psychometric properties of the itch numeric rating scale, skin pain numeric rating scale, and atopic dermatitis sleep scale in adult patients with moderate-to-severe atopic dermatitis. Health Qual Life Outcomes, 2021; 19(1):247–247.
51.
ReichA, RiepeC, AnastasiadouZ, et al.Itch assessment with visual analogue scale and numerical rating scale: determination of minimal clinically important difference in chronic itch. Acta Derm Venereol, 2016; 96(7):978–980.
52.
LeshemYA, ChalmersJR, ApfelbacherC, et al.Measuring atopic eczema control and itch intensity in clinical practice: a consensus statement from the harmonising outcome measures for eczema in clinical practice (HOME-CP) initiative. JAMA Dermatol, 2022; 158(12):1429–1435.
53.
ReichA, HeisigM, PhanNQ, et al.Visual analogue scale: evaluation of the instrument for the assessment of pruritus. Acta Derm Venereol, 2012; 92(5):497–501.
54.
DesaiNS, PoindexterGB, MonthropeYM, et al.A pilot quality-of-life instrument for pruritus. J Am Acad Dermatol, 2008; 59(2):234–244.
55.
EricksonS, KimBS. Research techniques made simple: itch measurement in clinical trials. J Invest Dermatol, 2019; 139(2):264–269.e261.
56.
ElmanS, HynanLS, GabrielV, et al.The 5-D itch scale: a new measure of pruritus. Br J Dermatol, 2010; 162(3):587–593.
57.
PatelKR, SingamV, VakhariaPP, et al.Measurement properties of three assessments of burden used in atopic dermatitis in adults. Br J Dermatol, 2019; 180(5):1083–1089.
58.
VakhariaPP, ChopraR, SacotteR, et al.Burden of skin pain in atopic dermatitis. Ann Allergy Asthma Immunol, 2017; 119(6):548–552.e543.
59.
StänderS, SimpsonEL, Guttman-YasskyE, et al.Clinical relevance of skin pain in atopic dermatitis. J Drugs Dermatol, 2020; 19(10):921–926.
60.
ChengB, PallerA, GriffithJ, et al.Clinical characterization of skin pain in children with atopic dermatitis. J Allergy Clin Immunol, 2021; 147(2):AB30.
61.
HuetF, ShourickJ, SéitéS, et al.Pain in atopic dermatitis: an online population-based survey. Acta Derm Venereol, 2020; 100(14):adv00198.
62.
SilverbergJI, SimpsonEL, Guttman-YasskyE, et al.Dupilumab significantly modulates pain and discomfort in patients with atopic dermatitis: a post hoc analysis of 5 randomized clinical trials. Dermatitis, 2021; 32(1S):S81–S91.
63.
DawnA, PapoiuADP, ChanYH, et al.Itch characteristics in atopic dermatitis: results of a web-based questionnaire. Br J Dermatol, 2009; 160(3):642–644.
64.
MaaroufM, KromenackerB, CapozzaKL, et al.Pain and itch are dual burdens in atopic dermatitis. Dermatitis, 2018; 29(5):278–281.
65.
NewtonL, DeLozierAM, GriffithsPC, et al.Exploring content and psychometric validity of newly developed assessment tools for itch and skin pain in atopic dermatitis. J Patient Rep Outcomes, 2019; 3(1):42.
66.
GrantL, Seiding LarsenL, TrenneryC, et al.Conceptual model to illustrate the symptom experience and humanistic burden associated with atopic dermatitis in adults and adolescents. Dermatitis, 2019; 30(4):247–254.
67.
SilverbergJI, GelfandJM, MargolisDJ, et al.Pain is a common and burdensome symptom of atopic dermatitis in United States adults. J Allergy Clin Immunol Pract, 2019; 7(8):2699–2706.e2697.
68.
HumphreyL, SymondsT, GableJ, et al.Validity and interpretation of a skin pain numeric rating scale among adults and adolescents with atopic dermatitis. Value Health, 2017; 20(9):A806.
69.
SilverbergJI.Validity and reliability of a novel numeric rating scale to measure skin-pain in adults with atopic dermatitis. Arch Dermatol Res, 2021; 313(10):855–861.
70.
JeonC, YanD, NakamuraM, et al.Frequency and management of sleep disturbance in adults with atopic dermatitis: a systematic review. Dermatol Ther (Heidelb), 2017; 7(3):349–364.
71.
RamirezFD, ChenS, LanganSM, et al.Association of atopic dermatitis with sleep quality in children. JAMA Pediatr, 2019; 173(5):e190025–e190025.
72.
ChangYS, ChiangBL. Sleep disorders and atopic dermatitis: a 2-way street?. J Allergy Clin Immunol, 2018; 142(4):1033–1040.
73.
PuellesJ, FofanaF, RodriguezD, et al.Psychometric validation and responder definition of the sleep disturbance numerical rating scale in moderate-to-severe atopic dermatitis. Br J Dermatol, 2022; 186(2):285–294.
74.
LeiDK, YousafM, JanmohamedSR, et al.Validation of patient-reported outcomes information system sleep disturbance and sleep-related impairment in adults with atopic dermatitis*. Br J Dermatol, 2020; 183(5):875–882.
75.
CharmanCR, VennAJ, WilliamsHC. The patient-oriented eczema measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients' perspective. Arch Dermatol, 2004; 140(12):1513–1519.
76.
SchramME, SpulsPI, LeeflangMM, et al.EASI, (objective) SCORAD and POEM for atopic eczema: responsiveness and minimal clinically important difference. Allergy, 2012; 67(1):99–106.
77.
SilverbergJI, MargolisDJ, BoguniewiczM, et al.Validation of five patient-reported outcomes for atopic dermatitis severity in adults. Br J Dermatol, 2020; 182(1):104–111.
78.
StalderJF, BarbarotS, WollenbergA, et al.Patient-oriented SCORAD (PO-SCORAD): a new self-assessment scale in atopic dermatitis validated in Europe. Allergy, 2011; 66(8):1114–1121.
79.
CoutanceauC, StalderJF. Analysis of correlations between patient-oriented SCORAD (PO-SCORAD) and other assessment scores of atopic dermatitis severity and quality of life. Dermatology, 2014; 229(3):248–255.
80.
SilverbergJI, GelfandJM, MargolisDJ, et al.Severity strata for POEM, PO-SCORAD, and DLQI in US adults with atopic dermatitis. Ann Allergy Asthma Immunol, 2018; 121(4):464–468.e463.
81.
FayeO, Meledie N'DjongAP, DiadieS, et al.Validation of the patient-oriented SCORing for atopic dermatitis tool for black skin. J Eur Acad Dermatol Venereol, 2020; 34(4):795–799.
LeshemYA, ChalmersJR, ApfelbacherC, et al.Measuring atopic eczema symptoms in clinical practice: the first consensus statement from the harmonising outcome measures for eczema in clinical practice initiative. J Am Acad Dermatol, 2020; 82(5):1181–1186.
EichenfieldLF, TomWL, ChamlinSL, et al.Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol, 2014; 70(2):338–351.
87.
BhanotA, PetersTJ, RiddMJ. Assessing the validity, responsiveness and reliability of the Recap measure of eczema control. Br J Dermatol, 2021; 184(5):955–957.
88.
FinlayAY, KhanGK. Dermatology life quality index (DLQI)—a simple practical measure for routine clinical use. Clin Exp Dermatol, 1994; 19(3):210–216.
89.
BothH, Essink-BotML, BusschbachJ, et al.Critical review of generic and dermatology-specific health-related quality of life instruments. J Invest Dermatol, 2007; 127(12):2726–2739.
90.
HeinlD, PrinsenCAC, DeckertS, et al.Measurement properties of adult quality-of-life measurement instruments for eczema: a systematic review. Allergy, 2016; 71(3):358–370.
91.
BlomeC, RadtkeMA, EissingL, et al.Quality of life in patients with atopic dermatitis: disease burden, measurement, and treatment benefit. Am J Clin Dermatol, 2016; 17(2):163–169.
92.
SimpsonEL, de Bruin-WellerM, BansalA, et al.Definition of clinically meaningful within-patient changes in POEM and CDLQI in children 6 to 11 years of age with severe atopic dermatitis. Dermatol Ther, 2021; 11(4):1415–1422.
93.
Lewis-JonesMS, FinlayAY, DykesPJ. The infants' dermatitis quality of life index. Br J Dermatol, 2001; 144(1):104–110.
94.
BasraMK, SalekMS, CamilleriL, et al.Determining the minimal clinically important difference and responsiveness of the Dermatology Life Quality Index (DLQI): further data. Dermatology, 2015; 230(1):27–33.
95.
SimpsonEL, de Bruin-WellerM, EckertL, et al.Responder threshold for patient-oriented eczema measure (POEM) and children's dermatology life quality index (CDLQI) in adolescents with atopic dermatitis. Dermatol Ther (Heidelb), 2019; 9(4):799–805.
96.
AliF, VyasJ, FinlayAY. Counting the burden: atopic dermatitis and health-related quality of life. Acta Derm Venereol, 2020; 100(12):adv00161.
97.
ChrenMM. TheSkindex instruments to measure the effects of skin disease on quality of. life. Dermatol Clin, 2012;30(2):231–6, xiii.
98.
SilverbergJI, LaiJS, KantorRW, et al.Development, validation, and interpretation of the PROMIS itch questionnaire: a patient-reported outcome measure for the quality of life impact of itch. J Invest Dermatol, 2020; 140(5):986–994.e986.
99.
PrinsenCAC, LindeboomR, SprangersMAG, et al.Health-related quality of life assessment in dermatology: interpretation of Skindex-29 scores using patient-based anchors. J Invest Dermatol, 2010; 130(5):1318–1322.
100.
SegawaE, SchaletB, CellaD. A comparison of computer adaptive tests (CATs) and short forms in terms of accuracy and number of items administrated using PROMIS profile. Qual Life Res, 2020; 29(1):213–221.
101.
SilverbergJI, KantorRW, DalalP, et al.A comprehensive conceptual model of the experience of chronic itch in adults. Am J Clin Dermatol, 2018; 19(5):759–769.
102.
SchochD, SommerR, AugustinM, et al.Patient-reported outcome measures in pruritus: a systematic review of measurement properties. J Invest Dermatol, 2017; 137(10):2069–2077.
103.
SchwartzmanG, LeiD, YousafM, et al.Validity and reliability of patient-reported outcomes measurement information system global health scale in adults with atopic dermatitis. J Am Acad Dermatol, 2021; 85(3):636–644.
104.
ThyssenJP, HamannCR, LinnebergA, et al.Atopic dermatitis is associated with anxiety, depression, and suicidal ideation, but not with psychiatric hospitalization or suicide. Allergy, 2018; 73(1):214–220.
105.
SilverbergJ, GelfandJM, MargolisD, et al. Symptoms and diagnosis of anxiety and depression in atopic dermatitis in U.S. adults. Br J Dermatol, 2019; 181(3):554–565.
106.
SilverbergJ, SoongW, LockshinB, et al.Dupilumab improves symptoms of anxiety and depression in adults and adolescents with moderate-to-severe atopic dermatitis: a post hoc analysis of three phase 3 trials (LIBERTY AD SOLO 1 & 2 and ADOL). J Allergy Clin Immunol, 2020; 145(2):AB191.
107.
SilverbergJI, LeeB, LeiD, et al.Measurement properties of patient health questionnaire 9 and patient health questionnaire 2 in adult patients with atopic dermatitis. Dermatitis, 2021; 32(4):225–231.
108.
SilverbergJI, GelfandJM, MargolisDJ, et al.Measurement properties of the hospital anxiety and depression scale used in atopic dermatitis in adults. J Invest Dermatol, 2019; 139(6):1388–1391.
109.
SnaithRP.The hospital anxiety and depression scale. Health Qual Life Outcomes, 2003; 1:29–29.
110.
SpitzerRL, KroenkeK, WilliamsJBW, et al.A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med, 2006; 166(10):1092–1097.
111.
KageP, PoblotzkiL, ZeynalovaS, et al.Depression, anxiety, and suicidal ideation in patients with atopic eczema in a prospective study in Leipzig, Germany. Int Arch Allergy Immunol, 2022; 183(4):409–414.
112.
García-CampayoJ, Pérez-YusMC, García-BustinduyM, et al.Early detection of emotional and behavioral disorders in dermatology. Actas Dermosifiliogr, 2016; 107(4):294–300.
113.
ChangYS, ChouYT, LeeJH, et al.Atopic dermatitis, melatonin, and sleep disturbance. Pediatrics, 2014; 134(2):e397–e405.
114.
EsaaF, PrezzanoJ, PentlandA, et al.The utility of PROMIS domain measures in dermatologic care. Arch Dermatol Res, 2021; 313(1):17–24.
115.
KadriO, JildehTR, MeldauJE, et al.How long does it take for patients to complete PROMIS scores? An assessment of PROMIS CAT questionnaires administered at an ambulatory sports medicine clinic. Orthop J Sports Med, 2018; 6(8):2325967118791180.
